Bidding War Heats Up for Metsera’s PD-(L)1xVEGF Bispecific Therapy
The competition for Metsera’s PD-(L)1xVEGF bispecific therapy has intensified, prompting significant interest from major pharmaceutical companies. This race represents a critical moment in the development of innovative cancer treatments, as…